Not provided
Not provided
Not provided
Not provided
Not provided
Translational scientist left university
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.
This research study will retrospectively examine 1395 patients from the University of Alabama and the University of Oklahoma Stephenson Cancer Center (OU-SCC) pancreatic cancer cohorts. The prospective arm, will enroll a total of 100 eligible volunteers at the OU-SCC. The demographic and medical data from the retrospective and prospective arms will be combined (1495 patients) to ascertain any racial disparities in pancreatic cancer patients with cachexia. Perspective volunteers at the OU-SCC will undergo routine tests to determine if their cancer is operable. Pancreatic tumors will be removed from the eligible patients, as part of their normal standard of care and will be examined for genes that may be related to unexplained muscle loss and compared to tumor tissue from other patients with pancreatic cancer. An optional hand strength exam, and standing on a scale that measures weight, muscle, and body fat will be available to OU-SCC patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pancreatic Cancer Cohort | All eligible adenocarcinoma pancreatic cancer patients with operable cancer. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pancreatic cancer microRNA and messenger RNA expression. | Other | Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of African American pancreatic cancer patients with weight loss and cachexia. | Evaluate weight loss and the markers of cachexia, albumin and psoas cross-sectional area, to see if African Americans with pancreatic cancer patients experience Grade I-IV cachexia at a higher frequency than other racial groups. | 1 - 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Differences in microRNA and messenger RNA tumor expression profiles in all cancer patients undergoing pancreatic surgery. | Assess fold-change expression differences in microRNA and messenger RNA tumor expression profiles in all cancer patients undergoing pancreatic surgery. | 1 - 12 months |
| Differences in cachexia-associated RNA signatures in African American pancreatic cancer patients, and other racial groups. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The study population is inclusive of all races, ethnicities, and gender. Enrollment into the study is restricted to Stephenson Cancer Center site, part of the University Oklahoma Health Sciences Center.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ajay Jain, MD | University of Oklahoma Stephenson Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73117 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010190 | Pancreatic Neoplasms |
| D002100 | Cachexia |
| ID | Term |
|---|---|
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004701 | Endocrine Gland Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
After surgical removal of the pancreatic cancer, part of the tumor tissue will be collected to analyze genes and RNA related to muscle loss in patients with pancreatic tumors. A portion of the tumor will be archived in a repository for future use related to this study.
Assess fold-change expression differences in cachexia-associated RNA signatures in African American pancreatic cancer patients, and other racial groups. |
| 1 - 12 months |
| D004066 |
| Digestive System Diseases |
| D010182 | Pancreatic Diseases |
| D004700 | Endocrine System Diseases |
| D015431 | Weight Loss |
| D001836 | Body Weight Changes |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D013851 | Thinness |